Class / Patent application number | Description | Number of patent applications / Date published |
514210400 | 16 to 24 amino acid residues in the peptide chain | 76 |
20100267650 | Dual Chain Synthetic Heparin-Binding Growth Factor Analogs - The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices. | 10-21-2010 |
20100267651 | T CELL ANTIGEN RECEPTOR PEPTIDES - The present invention provides peptides which affect T-cells, presumably by action on the T-cell antigen receptor. The present invention further relates to the therapy of various inflammatory and autoimmune disease states involving the use of these peptides. Specifically, the peptides are useful in the treatment of disorders where T-cells are involved or recruited. In one aspect the peptides have the formula: | 10-21-2010 |
20100305050 | PROTEIN PRODUCT WITH MODIFIED ANTIGENICITY - A bovine casein protein hydrolysate prepared using an enzyme having broad spectrum endopeptidase activity has low residual antigenicity properties in mammals compared to intact casein protein, The composition is useful as an ingredient in foods, beverages, pharmaceutical and cosmetic products. A hydrolysate prepared using Alcalase™ with a degree of hydrolysis of 19.88% has very desirably low antigenicity characteristics. | 12-02-2010 |
20100331263 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS - The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease. | 12-30-2010 |
20100331264 | PRESERVING SECONDARY PEPTIDE STRUCTURE - A method of preserving the α-helix secondary structure of N-Acetyl-D-Asp-D-Trp-D-Phe-D-Lys-D-Ala-D-Phe-D-Tyr-D-Asp-D-Lys-D-Val-D-Ala-D-Glu-D-Lys-D-Phe-D-Lys-D-Glu-D-Ala-D-Phe-Amide or N-Acetyl-L-Asp-L-Trp-L-Phe-L-Lys-L-Ala-L-Phe-L-Tyr-L-Asp-L-Lys-L-Val-L-Ala-L-Glu-L-Lys-L-Phe-L-Lys-L-Glu-L-Ala-L-Phe-Amide and compositions comprising such peptides are disclosed. | 12-30-2010 |
20110015138 | INHIBITION OF INFLAMMATION USING ANTAGONISTS OF MUC1 - The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling. | 01-20-2011 |
20110105416 | Novel Antimicrobial Peptides - The present invention relates to a peptide of linear, non-cyclic structure consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking (23) G or lacking. Further, the invention relates to a nucleic acid molecule encoding the peptide of the invention, an expression vector comprising the nucleic acid molecule of the invention, a host cell which may be grown in cell culture comprising the vector of the invention, and a method of producing the peptide of the invention comprising culturing the host cell of the invention and collecting the peptide produced. Also, the present invention relates to a pharmaceutical composition comprising the peptide of the invention, the peptide produced by the method of the invention, the nucleic acid molecule of the invention, the expression vector of the invention or the host cell of the invention and a kit comprising the peptide of the invention, the peptide produced by the method of the invention, the nucleic acid molecule of the invention, the expression vector of the invention or the host cell of the invention. | 05-05-2011 |
20110218157 | METHODS FOR TREATING IMMUNE-MEDIATED DENGUE FEVER INFECTIONS AND ANTIBODY-DEPENDENT ENHANCEMENT OF DENGUE FEVER INFECTIONS, INCLUDING DENGUE HEMORRHAGIC FEVER AND DENGUE SHOCK SYNDROME - Polypeptides and other compounds that can bind specifically to the C | 09-08-2011 |
20110224153 | Asthma Associated Factors as Targets for Treating Atopic Allergies Including Asthma and Related Disorders - A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual. | 09-15-2011 |
20110237524 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 09-29-2011 |
20110288036 | Methods for Treating or Preventing Vascular Graft Failure - The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, and a pharmaceutically acceptable carrier. The methods also are clinically useful for treating a pre-atherosclerotic intimal hyperplasia condition. | 11-24-2011 |
20110294748 | Insulin-like growth factor 1 receptor binding peptides - The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing. | 12-01-2011 |
20120022006 | B-LYMPHOCYTE STIMULATOR BINDING POLYPEPTIDES AND METHODS BASED THEREON - Binding polypeptides that specifically bind B lymphocyte stimulator protein or B lymphocyte stimulator-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate function of B lymphocyte stimulator or B lymphocyte stimulator receptor, comprising B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate B lymphocyte stimulator function or B lymphocyte stimulator receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator. | 01-26-2012 |
20120108524 | VACCINE COMPRISING AMB A 1 PEPTIDES FOR USE IN THE TREATMENT OF RAGWEED ALLERGY - The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen. | 05-03-2012 |
20120108525 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 05-03-2012 |
20120115797 | PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME - Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein. | 05-10-2012 |
20120122803 | ALPHA-CONOTOXIN MII ANALOGS - The invention relates to novel conopeptides and/or novel uses of conopeptides. The conopeptides of the invention are analogs of α-Conotoxin MII that are selective for α6-containing nAChRs as described herein. | 05-17-2012 |
20120129790 | METHODS OF USE OF EPSILON INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN - The disclosure herein relates to modified εPKC inhibitory peptides, methods of generating such peptides, and method for using εPKC inhibitory peptides for the treatment of pain. | 05-24-2012 |
20120142614 | Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis - A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps. | 06-07-2012 |
20120149652 | USE OF PEPTIDES COMPRISING POST-TRANSLATIONAL MODIFICATIONS IN THE TREATMENT OF AUTOIMMUNE PATHOLOGIES - Peptides including post-translational-type modifications, such as phosphorylation or acetylation of one or more amino acids, are provided. Processes for obtaining the peptides, pharmaceutical compositions including the peptides and methods for treating autoimmune diseases using the peptides are also provided. | 06-14-2012 |
20120165275 | Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules - Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis. | 06-28-2012 |
20120245104 | NOVEL RETRO-INVERSO LEPTIN PEPTIDE ANTAGONISTS - Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling in the leptin-responsive cell. Administration of the peptide effectively prevents embryo implantation in a mammal to which the peptide has been administered. Also disclosed herein is a method for identifying a peptide antagonist of ObR, wherein the peptide comprises a leptin sequence. Further disclosed are truncations, modifications and retro-inversions of the peptides of the present invention. | 09-27-2012 |
20120270811 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY - A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function. | 10-25-2012 |
20120329728 | COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY - The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members. | 12-27-2012 |
20130012456 | COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER - Compositions and methods are provided including a peptide derived from the loop2 domain of the lynx1 protein for transport to a target inside the blood brain barrier. | 01-10-2013 |
20130012457 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure wherein the material comprises a pair of self assembling complementary polypeptides. | 01-10-2013 |
20130018004 | Novel Protein Peptide Hydrogels - The present invention broadly provides novel peptides that can be used to form hydrogels. The peptides are short (preferably 30 amino acid residues or less) and include hydrophilic and hydrophobic segments joined by a turning segment. The hydrogels are formed by altering the pH of a solution of these peptides to an acidic level, or by introducing a source of ions into a solution of these peptides. The resulting hydrogels are shear thinning gels that have high storage moduli and high rates of recovery after destruction. They find use in medical applications, including tissue engineering. | 01-17-2013 |
20130029920 | Metal Nanoparticles - A metal nanoparticle-phosphopeptide complex comprising a metal nanoparticle and a phosphopeptide is provided. The phosphopeptide comprises two or more contiguous peptide motifs and two or more phosphorus-containing groups capable of interacting with the surface of the metal nanoparticle. The amino acids at the equivalent position in each peptide motif have similar structural and/or electronic properties. Each phosphorus-containing group is bound to an amino acid in the two or more contiguous peptide motifs. Methods for preparing the metal nanoparticle-phosphopeptide complex are also provided. | 01-31-2013 |
20130029921 | INHIBITING PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF - The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis. | 01-31-2013 |
20130040900 | PEPTIDES EFFECTIVE IN THE TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS - The invention is directed to methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides comprising a part of the amino acid sequence of a neural thread protein. | 02-14-2013 |
20130065840 | METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY - Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject. | 03-14-2013 |
20130109635 | Humanin Decreases Liver Fat and Visceral Fat Accumulation | 05-02-2013 |
20130123202 | COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES - Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides. | 05-16-2013 |
20130130995 | Treatments for Gastrointestinal Disorders - Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein. | 05-23-2013 |
20130203685 | PROTEASE TARGETING AGENTS - Peptides having the ability to block the activity of acyl-aminoacid releasing enzymes such as AARE or APEH are disclosed. Derivatives of the peptides include oligomers or multimers of the peptide linked to a common scaffold moiety such as a tri-functional amino acid and peptides linked to PEG and fatty acids. Pharmaceutical compositions that include the peptide are also disclosed and can be used to treat various diseases such as cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases. | 08-08-2013 |
20130231294 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF, ANALOGS AND BIOACTIVE FRAGMENTS - The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders. | 09-05-2013 |
20130244956 | CAMPTOTHEAN-PEPTIDE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptidic moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues. | 09-19-2013 |
20130331343 | Materials Presenting Notch Signaling Molecules To Control Cell Behavior - The invention provides a solution to the problem of delivering molecules in a physiologically relevant manner to direct cell fate. For example, a Notch ligand molecule is presented in a microenvironment that mimics the environment encountered in vivo. Accordingly, the invention features a cell delivery vehicle comprising a biocompatible hydrogel or polymer and a composition that binds to a Notch receptor and methods of directing cell fate, e.g., stem cell differentiation, using such compositions. | 12-12-2013 |
20140038909 | TISSUE OCCLUDING AGENT - There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. | 02-06-2014 |
20140051646 | CELL PENETRATING PEPTIDES - The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule. | 02-20-2014 |
20140051647 | SYNTHETIC PEPTIDE THAT INDUCES EXPRESSION OF TNF RECEPTOR 2 AND USE THEREOF - This invention provides a TNFR2 expression-inducing composition including as an active ingredient a peptide having TNFR2 expression-inducing activity, and a method for producing cells that express TNFR2 selectively by use of the composition. The cell production method provided by this invention includes: culturing at least one species of cells capable of expressing TNF receptor 2, and supplying the cells with a synthetic peptide consisting of a nuclear localization signal sequence (NLS) or a nucleolar localization signal sequence (NoLS) to enhance TNFR2 expression in the cells. | 02-20-2014 |
20140066387 | FUNCTIONALIZED BIOMATERIALS FOR TISSUE REGENERATION - The present invention concerns the field of functionalized self-assembling peptides suitable for obtaining hydrogels for use in a wide range of applications in the biomedical field, such as for the development of biomaterials for regenerative medicine and basic science research. | 03-06-2014 |
20140066388 | MITOCHONDRIAL-TARGETED CATIONIC NANOPARTICLES COMPRISING CAMKII INHIBITORS AND USES THEREOF FOR TREATING AND PREVENTING DISEASES AND DISORDERS ASSOCIATED WITH CAMKII ACTIVITY - Disclosed are compositions and methods for treating or preventing diseases or disorders associated with mitochondrial CaMKII activity. | 03-06-2014 |
20140088025 | LYOPHILIZATION OF SYNTHETIC LIPOSOMAL PULMONARY SURFACTANT - Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. A method of making lyophilized pulmonary surfactants is described. | 03-27-2014 |
20140088026 | LYOPHILIZATION OF SYNTHETIC LIPOSOMAL PULMONARY SURFACTANT - Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described. | 03-27-2014 |
20140113874 | Modified Compstatin With Improved Stability And Binding Properties - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These cyclic compounds are modified to improve stability while maintaining substantially equivalent complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs in which the disulfide bond between C2 and C12 is modified via a thioether bond to form a cystathionine. | 04-24-2014 |
20140135276 | LIPOPEPTIDE INHIBITORS OF RAS ONCOPROTEINS - The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal α-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same. | 05-15-2014 |
20140213534 | INTESTINAL HYPERPERMEABILITY AND PREVENTION OF SYSTEMIC DISEASE - Compositions for and methods of preventing or reducing the severity intestinal hyperpermeabilization in an individual are disclosed. Compositions for and methods of preventing or reducing the severity of a disease or condition caused or exacerbated by intestinal hyperpermeabilization in an individual identified as being at risk of a disease or condition caused or exacerbated by intestinal hyperpermeabilization are also disclosed. Compositions for and methods of treating an individual who has been identified as having a disease or condition caused or exacerbated by intestinal hyperpermeabilization are additionally disclosed. | 07-31-2014 |
20140296163 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 10-02-2014 |
20140329765 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 11-06-2014 |
20140342996 | Treatments for Gastrointestinal Disorders - The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation. | 11-20-2014 |
20140378395 | Peptides for the Treatment of Hearing - Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis media, noise-induced hearing loss, age-related hearing loss, and improvement of ordinary hearing. | 12-25-2014 |
20150051159 | LACTOCOCCUS LACTIS STRAINS | 02-19-2015 |
20150065435 | REAGENTS AND METHODS FOR TREATING DENTAL DISEASE - The present invention provides reagents and methods for treating dental disease. | 03-05-2015 |
20150072941 | DPY-30 Binding Peptides - Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to RSP3 or Ash2L and that bind to Dpy-30. | 03-12-2015 |
20150080320 | MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS - The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer. | 03-19-2015 |
20150080321 | WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE - A compound represented by the formula (1): | 03-19-2015 |
20150087604 | ANTI-FATTY ACID SYNTHASE POLYPEPTIDE AND USE THEREOF - The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (FAS) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of FAS at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of FAS. Said polypeptide and related peptidomimetics, including functional fragments or functional varieties thereof, and the genes encoding therefor, can be widely used in preventing and treating tumors such as liver cancer, and diseases closely related to the metabolism of fatty acid synthase, such as fatty liver and obesity. | 03-26-2015 |
20150105336 | MUCOSA-ELEVATING AGENT - Provided is a mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a β structure in an aqueous solution at physiological pH and/or in the presence of cations. | 04-16-2015 |
20150111835 | MODIFIED PEPTIDES AND THEIR USE FOR TREATING AUTOIMMUNE DISEASES - The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications. | 04-23-2015 |
20150126460 | CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY - The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension. | 05-07-2015 |
20150141350 | DENDRIMER BASED NANODEVICES FOR THERAPEUTIC AND IMAGING PURPOSES - A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment. | 05-21-2015 |
20150148302 | Peptide Inhibitors of Caspase 2 Activation - The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease. | 05-28-2015 |
20150355179 | CDKACT BIOSENSORS-FLUORESCENT POLYPEPTIDE TO PROBE THE ACTIVITY OF CDK/CYCLIN KINASES IN VITRO, IN CELLULO AND IN VIVO - This invention relates to compounds comprising a polypeptide and a fluorophore, wherein the polypeptide is capable of being phosphorylated by a Cyclin-Dependent Kinase (CDK) and/or a Cyclin-CDK complex on a specific site and wherein the fluorescence of said fluorophore changes upon phosphorylation of said specific site of said polypeptide. The invention also relates to the use of such compounds or of compositions comprising such compounds for medical imaging. The invention furthermore relates to methods for determining if at least one CDK and/or Cyclin-CDK complex is active, for determining changes in at least one CDK and/or Cyclin-CDK complex activity, for the in vitro diagnosis of Cyclin-dependent kinase hyperactivation in a subject. | 12-10-2015 |
20150374784 | COMPOSITIONS AND METHODS FOR REDUCING GERM CELL DEATH - Described herein are methods of protecting germ cells in a subject from cell death induced by a chemotherapeutic agent by, in part, administering a composition comprising one or more humanin polypeptides to the subject. Also described herein are methods of inhibiting a reduction or decrease in fertility in a subject wherein the reduction or decrease in fertility is due to a chemotherapeutic agent. | 12-31-2015 |
20160000859 | PEPTIDE ADDITIVES FOR ENHANCING ACCEPTANCE AND INGESTION OF EDIBLES BY RODENTS AND USES THEREOF - Methods of using of guanylin family peptides to induce food or odor preferences in mammals are provided, along with methods for inducing feeding responses in mammals, and methods of controlling pest populations of mammals, such as rodents. | 01-07-2016 |
20160008422 | COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF | 01-14-2016 |
20160024154 | BIOCOMPATIBLE PROTEIN, BIOCOMPATIBLE PROTEIN GEL AND BIOCOMPATIBLE CONDUCTING PROTEIN GEL COMPRISING THE PROTEIN AND METHOD FOR PREPARING THE SAME - Provided herein is a biocompatible protein, and biocompatible protein gel and conductive protein gel including the biocompatible protein, and preparing method thereof, the amino acid sequence of the biocompatible protein being Lys-X-Lys-Glu-X-Phe-Phe-X-Lys-Glu-X-Phe-Phe-X-Lys-Glu-X-Tyr, X being any one or more of hydrophobic amino acids, and the method including synthesizing a protein that causes no rejections from human bodies and that is not easily degradable, thereby providing an advantage of being utilized as a conductive biomaterial having biocompatibility and biodegradability in regenerative medical fields such as 3D bioprinting. | 01-28-2016 |
20160030628 | TREATMENT FOR BILE LEAKAGE - Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. | 02-04-2016 |
20160031952 | Amyloidosis-inhibiting Polypeptides and Their Use - Isolated polypeptides that possess an a-sheet structure are disclosed that can be used to treat or diagnose amyloid diseases. | 02-04-2016 |
20160052967 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES - An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids. | 02-25-2016 |
20160058876 | Polyplexes - The present disclosure relates to compounds comprising (i) an active agent, wherein the active agent includes a charge at a predetermined pH, (ii) a polymer, wherein the polymer includes an opposite charge than the active agent at the predetermined pH; and (iii) a polyplex comprising the peptide and the polymer electrostatically bond together at the predetermined pH. In some embodiments, the active agent is a peptide, such as a peptide comprising MAPKAP kinase II inhibitory peptide, and in some embodiments the peptide includes a cell-penetrating peptide. In further embodiments, the disclosure provides methods for treating a disease or condition by administering a composition according to the present disclosure to a subject in need thereof. | 03-03-2016 |
20160115201 | PEPTIDES BINDING TO PARALLEL-STRANDED G-QUADRUPLEXES - This invention relates to a peptide comprising or consisting of the amino acid sequence of SEQ ID NO:1 or a derivative thereof. The present invention also relates to conjugates of said peptide, the use of the peptide or the conjugate as a medicament and to methods for the detection of parallel-stranded G-quadruplexes. | 04-28-2016 |
20160130302 | COMPOSITIONS AND METHODS FOR SPECIFIC REGULATION OF PYRUVATE DEHYDROGENASE KINASE - A peptide composition is provided which specifically inhibits the ability of δ-protein kinase C (δPKC) to phosphorylate pyruvate dehydrogenase kinase (PDK) under ischemic conditions. The peptide composition is useful for treating or reducing tissue damage resulting from ischemia and/or reperfusion. | 05-12-2016 |
20160158311 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer. | 06-09-2016 |
20160168201 | Methods and Compositions for the Treatment of Gastrointestinal Disorders | 06-16-2016 |